BioArctic employs Gunilla Andersson as Senior Director HR December 19, 2018 08:00 Non Regulatory Read more
BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance December 14, 2018 08:00 Regulatory Read more
BioArctic to present at Jefferies 2018 London Healthcare Conference on November 15 November 13, 2018 08:00 Non Regulatory Read more
BioArctic is awarded grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s November 12, 2018 08:00 Regulatory Read more
BioArctic presents Nomination Committee and publishes financial calendar 2019 November 6, 2018 20:00 Regulatory Read more
BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease November 2, 2018 02:30 Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018 October 30, 2018 09:15 Non Regulatory Read more
BioArctic announces additional BAN2401 Phase 2b study results in early Alzheimer’s disease presented by Eisai at the 2018 CTAD conference October 25, 2018 14:30 Regulatory Read more
BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease October 21, 2018 09:00 Regulatory Read more
BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD October 18, 2018 01:30 Non Regulatory Read more
BioArctic receives European patent protection for a medical device for treatment of patients with Complete Spinal Cord Injury October 3, 2018 14:30 Regulatory Read more
BioArctic signs a research agreement with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease September 13, 2018 10:00 Regulatory Read more
BioArctic expands the research collaboration with Uppsala University concerning antibody-based diagnostic imaging of the brain in Alzheimer patients September 3, 2018 14:30 Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018 August 14, 2018 08:00 Non Regulatory Read more
BioArctic obtains exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai August 7, 2018 20:00 Regulatory Read more
BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018 July 25, 2018 22:30 Regulatory Read more
BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disease will be webcast live from AAIC 2018 by Eisai July 18, 2018 22:00 Regulatory Read more
BioArctic receives regulatory approval in Finland for a clinical study in patients with Complete Spinal Cord Injury July 10, 2018 12:30 Regulatory Read more
BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018 July 10, 2018 03:00 Regulatory Read more
BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s Disease July 6, 2018 01:30 Regulatory Read more
BioArctic announces changes in the Management Team effective September 1, 2018 June 27, 2018 07:00 Regulatory Read more
Report from the Annual General Meeting in BioArctic AB (publ) May 15, 2018 20:00 Regulatory Read more
BioArctic extends the research collaboration with Uppsala University regarding new antibody technology May 14, 2018 10:30 Regulatory Read more
Inclusion completed of patients with complete spinal cord injury in the first panel of BioArctic’s ongoing study April 25, 2018 11:00 Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018 April 12, 2018 08:00 Non Regulatory Read more
BioArctic receives regulatory approval in Norway for a clinical study in patients with Complete Spinal Cord Injury March 21, 2018 13:00 Regulatory Read more
BioArctic receives patent protection in Japan for a medical device for treatment of patients with Complete Spinal Cord Injury March 19, 2018 13:00 Regulatory Read more
BioArctic receives regulatory approval in Estonia for a clinical study in patients with Complete Spinal Cord Injury February 21, 2018 11:00 Regulatory Read more
Invitation to presentation of BioArctic’s Full Year Report 2017 on February 20, 2018 February 5, 2018 17:30 Regulatory Read more
BioArctic receives US patent protection for a method with a medical device for treatment of patients with Complete Spinal Cord Injury February 2, 2018 08:00 Regulatory Read more
